Clinical Trials
Aripiprazole is evaluated across numerous clinical trials spanning Phase 1 safety evaluations to Phase 4 post-marketing studies. These trials assess the efficacy, pharmacokinetics, and safety of the compound for psychiatric conditions including schizophrenia, bipolar I disorder, major depressive disorder, schizoaffective disorder, and tic disorders. Sponsored by academic medical institutions and pharmaceutical developers like Otsuka and Lundbeck, these research initiatives encompass active, completed, withdrawn, and upcoming studies.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06969755 | RECRUITING | Schizophenia Disorder |
Northwell Health |
2024-09-04 | PHASE4 |
| NCT06433635 | ACTIVE_NOT_RECRUITING | Bipolar I Disorder; Depression |
Massachusetts General Hospital |
2024-10-01 | PHASE4 |
| NCT07483294 | RECRUITING | Psychosis; Acute |
Northwell Health |
2025-11-01 | PHASE4 |
| NCT07714213 | NOT_YET_RECRUITING | Post-acute Infectious Syndrome (PAIS); Post-COVID-19 Condition (PCC or Long COVID) |
Christiana Franke |
2026-10-01 | PHASE2 |
| NCT07047651 | ACTIVE_NOT_RECRUITING | Treatment Resistant Schizophrenia; Treatment Resistant Bipolar Disorder |
Dr. Stavroula Rakitzi |
2025-06-04 | PHASE4 |
| NCT07565428 | RECRUITING | Negative Symptoms of Schizophrenia |
Minerva Neurosciences |
2026-04-23 | PHASE3 |
| NCT05545891 | NOT_YET_RECRUITING | Trichotillomania (Hair-Pulling Disorder); Dermatillomania |
University of Chicago |
2026-06 | PHASE2 |
| NCT07703956 | NOT_YET_RECRUITING | Schizophrenia |
Vigonvita Life Sciences |
2026-07-31 | PHASE2 |
| NCT07547384 | NOT_YET_RECRUITING | Schizophrenia |
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. |
2026-04-05 | |
| NCT07215884 | RECRUITING | Stuttering, Adult |
University of California, San Francisco |
2025-09-30 | PHASE1 |
| NCT04539951 | RECRUITING | Obsessive-Compulsive Disorder |
Shanghai Mental Health Center |
2020-09-22 | PHASE2 |
| NCT07011693 | NOT_YET_RECRUITING | Major Depressive Disorder (MDD) |
Xinyu Zhou |
2025-06-20 | PHASE4 |
| NCT05814640 | RECRUITING | Depression; Sequestra |
First Affiliated Hospital of Chongqing Medical University |
2023-02-20 | PHASE1; PHASE2 |
| NCT07153406 | NOT_YET_RECRUITING | Depressive Disorder |
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
2025-09-15 | PHASE3 |
| NCT06799559 | NOT_YET_RECRUITING | Schizophrenia |
Qilu Pharmaceutical Co., Ltd. |
2025-05 | PHASE3 |
| NCT06589817 | NOT_YET_RECRUITING | Acute Schizophrenia |
Chengdu Kanghong Pharmaceutical Group Co., Ltd. |
2024-10 | PHASE3 |
| NCT06937476 | ACTIVE_NOT_RECRUITING | Major Depressive Disorder (MDD); Rumination |
Central South University |
2025-05-08 | |
| NCT07550387 | COMPLETED | SCHIZOPHRENIA 1 (Disorder) |
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
2024-05-23 | PHASE2 |
| NCT06581302 | RECRUITING | Psychotic Disorders |
Shanghai Jiao Tong University School of Medicine |
2024-09-01 | |
| NCT04903353 | COMPLETED | Weight Gain; Autism Spectrum Disorder; Medication Side Effect |
Vanderbilt University Medical Center |
2022-02-01 | PHASE4 |
| NCT06236451 | COMPLETED | Schizophrenia |
All India Institute of Medical Sciences, Bhubaneswar |
2024-04-05 | PHASE4 |
| NCT03423680 | UNKNOWN | Depression, Bipolar |
Korea Otsuka Pharmaceutical Co., Ltd. |
2018-02-22 | PHASE3 |
| NCT06501339 | UNKNOWN | Clozapine Resistant Schizophrenia |
All India Institute of Medical Sciences, Bhubaneswar |
2024-08-10 | PHASE4 |
| NCT06060886 | UNKNOWN | Schizophrenia; Treatment-resistant Schizophrenia; Side Effect; Lipid Metabolism Disorders; Diabetes; NAFLD; Psychosis |
Consorcio Centro de Investigación Biomédica en Red (CIBER) |
2023-11-01 | PHASE4 |
| NCT06590298 | NOT_YET_RECRUITING | Psychosis; Metabolic Syndrome; Weight Gain |
Universiti Putra Malaysia |
2024-09-15 | PHASE4 |
| NCT05662306 | TERMINATED | Schizophrenia |
University of Miami |
2024-01-23 | PHASE4 |
| NCT05361993 | WITHDRAWN | Tic Disorders |
Children's Hospital of Fudan University |
2024-06-01 | PHASE4 |
| NCT05389046 | UNKNOWN | Outpatients / Inpatients With Depression |
Peking University |
2022-08-15 | |
| NCT05322031 | COMPLETED | Schizophrenia; Myelin Degeneration; Cognition Disorder |
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico |
2022-08-01 | PHASE4 |
| NCT05531591 | COMPLETED | Depression; Dementia; Mild Cognitive Impairment; Treatment Resistant Depression; Major Depressive Disorder; Treatment-Refractory Depression; Late Life Depression; Geriatric Depression |
Centre for Addiction and Mental Health |
2019-08-01 | PHASE4 |
| NCT03485417 | COMPLETED | Stimulant Use With Stimulant-Induced Psychotic Disorder (Diagnosis); Schizophrenia and Related Disorders; Stimulant Dependence; Stimulant Abuse; Pharmacotherapy |
The University of Hong Kong |
2019-06-01 | PHASE2; PHASE3 |
| NCT05868720 | UNKNOWN | The Goal of This Trial is to to Compare the Effect of Risperidone vs Aripiprazole in Terms of Change in Serum Glutathione Level |
All India Institute of Medical Sciences, Bhubaneswar |
2023-07-01 | |
| NCT05542264 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2022-11-15 | PHASE1 |
| NCT05766540 | UNKNOWN | Difference in the Change in Cardiovascular Risk in Treatment Resistant Schizophrenia |
All India Institute of Medical Sciences, Bhubaneswar |
2023-08-20 | PHASE4 |
| NCT06060886 | Not yet recruiting | Schizophrenia|Treatment-resistant Schizophrenia|Side Effect|Lipid Metabolism Disorders|Diabetes|NAFLD|Psychosis |
Consorcio Centro de Investigación Biomédica en Red (CIBER)|Instituto de Salud Carlos III |
2023-11-01 | Phase 4 |
| NCT05554627 | WITHDRAWN | Depressive Disorder, Major |
VA Office of Research and Development |
2023-10-27 | PHASE4 |
| NCT03510325 | COMPLETED | Schizophrenia |
Shanghai Mental Health Center |
2019-02-12 | PHASE3 |
| NCT05402111 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2022-06-13 | PHASE1 |
| NCT02918370 | COMPLETED | Bipolar Disorder; Alcoholism; Alcohol Abuse |
University of Texas Southwestern Medical Center |
2016-11 | PHASE3 |
| NCT03198078 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2017-06-30 | PHASE3 |
| NCT05103410 | COMPLETED | Anesthesia; Analgesia; Hysterotomy |
Ain Shams University |
2021-11-10 | PHASE4 |
| NCT04446234 | UNKNOWN | Schizophrenia |
Shanghai Mental Health Center |
2021-05 | PHASE4 |
| NCT05804721 | COMPLETED | Healthy |
Genuine Research Center, Egypt |
2022-10-10 | PHASE1 |
| NCT04203056 | TERMINATED | Schizophrenia; Schizoaffective Disorder, Depressive Type; Schizophreniform Disorder |
University of California, Los Angeles |
2019-12-16 | PHASE4 |
| NCT04765085 | WITHDRAWN | Tic Disorders |
Children's Hospital of Fudan University |
2021-03 | |
| NCT02977299 | COMPLETED | Treatment Resistant Major Depressive Disorder |
Massachusetts General Hospital |
2017-07-13 | PHASE4 |
| NCT05974241 | COMPLETED | Irritable Mood; ADHD |
Tri-Service General Hospital (TSGH) |
2017-04-21 | PHASE4 |
| NCT02357849 | TERMINATED | Attenuated Psychosis Syndrome |
Northwell Health |
2014-07 | PHASE4 |
| NCT05322031 | Unknown status | Schizophrenia|Myelin Degeneration|Cognition Disorder |
Fondazione IRCCS Ca'' Granda Ospedale Maggiore Policlinico |
2022-01-01 | Phase 4 |
| NCT03376763 | COMPLETED | Schizophrenia; Antipsychotics; Long-Acting Injection; LAI; Aripiprazole |
Korea Otsuka Pharmaceutical Co., Ltd. |
2017-11-21 | PHASE4 |
| NCT04907279 | Unknown status | Schizophrenia|Schizo Affective Disorder|Bipolar I Disorder |
Otsuka Canada Pharmaceutical Inc.|Lundbeck Canada Inc. |
2021-11-01 | -- |
| NCT03874494 | COMPLETED | Schizophrenia |
Otsuka Beijing Research Institute |
2019-11-27 | PHASE3 |
| NCT05532254 | COMPLETED | Healthy Subjects |
Future University in Egypt |
2021-02-14 | PHASE1 |
| NCT02339844 | COMPLETED | Schizophrenia |
University of Copenhagen |
2014-01 | PHASE4 |
| NCT03881449 | UNKNOWN | Schizophrenia; Major Depressive Disorder; Bi-Polar Disorder; Schizo Affective Disorder |
Durham VA Medical Center |
2019-04-04 | PHASE4 |
| NCT03883204 | UNKNOWN | Schizophrenia; Psychotic Disorders; Psychosis |
Fundación Marques de Valdecilla |
2015-01-01 | PHASE4 |
| NCT02960763 | COMPLETED | Treatment Resistant Depression; Major Depressive Disorder; Treatment-Refractory Depression; Late Life Depression; Geriatric Depression |
Washington University School of Medicine |
2017-02-24 | PHASE4 |
| NCT02146547 | COMPLETED | Schizophrenia |
UMC Utrecht |
2015-02 | PHASE4 |
| NCT04030143 | COMPLETED | Schizophrenia; Bipolar I Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2019-08-01 | PHASE1; PHASE2 |
| NCT03661983 | TERMINATED | Tourette's Disorder (TD) |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2018-10-13 | PHASE4 |
| NCT03790085 | UNKNOWN | Schizophrenia; Major Depressive Disorder; Anxiety Disorders |
Tianjin Medical University General Hospital |
2018-09-01 | EARLY_PHASE1 |
| NCT04234776 | UNKNOWN | Depressive Disorder |
University of Sao Paulo |
2018-04-03 | PHASE4 |
| NCT03487770 | COMPLETED | Autistic Disorder |
Otsuka Beijing Research Institute |
2018-04-09 | PHASE3 |
| NCT02630888 | UNKNOWN | Bipolar Disorder |
University of Sao Paulo |
2014-08 | PHASE2 |
| NCT03487783 | COMPLETED | Tourette Syndrome |
Otsuka Beijing Research Institute |
2018-05-02 | PHASE3 |
| NCT03289026 | COMPLETED | Acute Schizophrenia Episode |
Peking University |
2017-09-01 | PHASE4 |
| NCT03839251 | COMPLETED | Schizophrenia |
Chonbuk National University Hospital |
2018-06-01 | PHASE4 |
| NCT03148509 | UNKNOWN | Diagnosis and Treatment of Depression |
Peking University |
2017-06-01 | PHASE4 |
| NCT02574741 | COMPLETED | Autism Spectrum Disorder |
University of California, Los Angeles |
2012-06 | PHASE2 |
| NCT02431702 | COMPLETED | Schizophrenia; Psychotic Disorders |
Janssen Scientific Affairs, LLC |
2015-07-08 | PHASE3 |
| NCT03287505 | COMPLETED | Schizophrenia |
Otsuka Beijing Research Institute |
2017-06-23 | PHASE1 |
| NCT03557931 | COMPLETED | Schizophrenia |
Astellas Pharma Global Development, Inc. |
2018-07-13 | PHASE2 |
| NCT03285503 | COMPLETED | Schizophrenia |
Otsuka Beijing Research Institute |
2018-08-17 | PHASE1 |
| NCT02949752 | COMPLETED | Antipsychotics Weight Gain |
Institute of Mental Health, Singapore |
2016-08 | PHASE4 |
| NCT02926976 | UNKNOWN | Schizophrenia |
Shanghai Mental Health Center |
2016-11 | |
| NCT04030143 | Completed | Schizophrenia|Bipolar I Disorder |
Otsuka Pharmaceutical Development & Commercialization Inc. |
2019-08-01 | Phase 1|Phase 2 |
| NCT03172871 | COMPLETED | Schizophrenia |
Otsuka Beijing Research Institute |
2017-05-15 | PHASE3 |
| NCT03090503 | UNKNOWN | Schizophrenia; Psychotic Disorders; Psychosis |
Fundación Marques de Valdecilla |
2014-06 | PHASE4 |
| NCT03568500 | COMPLETED | Schizophrenia; Schizoaffective Disorder; First Episode Psychosis |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2018-05-21 | PHASE4 |
| NCT03854409 | COMPLETED | Schizophrenia; Bipolar I Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2019-01-31 | PHASE1 |
| NCT03881449 | Unknown status | Schizophrenia|Major Depressive Disorder|Bi-Polar Disorder|Schizo Affective Disorder |
Durham VA Medical Center|Otsuka Pharmaceutical Development and Commercialization Inc. |
2019-04-04 | Phase 4 |
| NCT02360319 | COMPLETED | Schizophrenia |
Vanguard Research Group |
2014-12-11 | PHASE4 |
| NCT03345979 | COMPLETED | Schizophrenia |
Alkermes, Inc. |
2017-11-15 | PHASE3 |
| NCT03854409 | Completed | Schizophrenia|Bipolar I Disorder |
Otsuka Pharmaceutical Development & Commercialization Inc.|PRA Health Sciences|H. Lundbeck A/S |
2019-01-31 | Phase 1 |
| NCT01129882 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2010-06-24 | PHASE3 |
| NCT02955654 | WITHDRAWN | Obsessive-Compulsive Disorder |
Shanghai Mental Health Center |
2017-09-01 | |
| NCT02237417 | COMPLETED | Schizophrenia |
University of Utah |
2014-09-01 | PHASE4 |
| NCT03643159 | TERMINATED | Schizophrenia; Bipolar 1 Disorder; Major Depressive Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2018-06-28 | PHASE4 |
| NCT02532491 | UNKNOWN | Schizophrenia; Psychotic Disorders |
Fundación Marques de Valdecilla |
2014-05 | PHASE4 |
| NCT03232710 | UNKNOWN | Bioequivalence |
Chengdu Kanghong Pharmaceutical Group Co., Ltd. |
2017-06-26 | |
| NCT03150771 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2017-06-14 | PHASE1 |
| NCT02697045 | COMPLETED | Schizophrenia |
Abdi İbrahim Otsuka |
2017-01-04 | PHASE4 |
| NCT03342963 | COMPLETED | Healthy Male Adults |
Otsuka Pharmaceutical Co., Ltd. |
2017-11-21 | PHASE1 |
| NCT02282085 | UNKNOWN | Schizophrenia |
Matt Byerly |
2014-12 | PHASE4 |
| NCT01446328 | COMPLETED | Schizophrenia; Psychotic Disorders |
Haukeland University Hospital |
2011-10 | PHASE4 |
| NCT03358277 | COMPLETED | Disruptive Mood Dysregulation Disorder |
Tri-Service General Hospital (TSGH) |
2014-11-19 | |
| NCT02634320 | COMPLETED | Schizophrenia |
Alkermes, Inc. |
2015-12 | PHASE4 |
| NCT02374567 | TERMINATED | Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders |
Hannover Medical School |
2015-01 | PHASE3 |
| NCT02717130 | TERMINATED | Schizophrenia |
Florida Atlantic University |
2016-06-08 | |
| NCT02007928 | COMPLETED | Dissociative Disorders; Schizophrenia |
Centre Hospitalier Universitaire de Nice |
2013-04 | |
| NCT01655706 | COMPLETED | Major Depressive Disorder |
University Health Network, Toronto |
2012-04-23 | PHASE3 |
| NCT01913327 | TERMINATED | Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder |
University of California, San Francisco |
2013-04 | PHASE4 |
| NCT03019887 | COMPLETED | Schizophrenia Relapse |
Juntendo University |
2011-04 | |
| NCT02472652 | TERMINATED | Sexual Dysfunction |
Gazda, Thomas D., M.D., PC |
2015-06 | PHASE4 |
| NCT01696617 | COMPLETED | Major Depressive Disorder |
Seoul National University Hospital |
2012-02-10 | PHASE4 |
| NCT02650102 | UNKNOWN | Schizophrenia |
Shanxi Medical University |
2013-01 | PHASE1; PHASE2 |
| NCT01338298 | COMPLETED | Hyperprolactinemia |
University of Maryland, Baltimore |
2011-01 | |
| NCT02634463 | COMPLETED | Immunoassay; Antipsychotic |
Janssen Research & Development, LLC |
2015-11-09 | PHASE1 |
| NCT01710709 | COMPLETED | Bipolar I |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2012-11 | PHASE3 |
| NCT01617460 | COMPLETED | Autistic Disorder |
Otsuka Pharmaceutical Co., Ltd. |
2012-09 | PHASE3 |
| NCT02722967 | COMPLETED | Schizophrenia; Major Depressive Disorder; Bipolar I Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2016-03 | PHASE2 |
| NCT02636842 | COMPLETED | Schizophrenia; Schizoaffective Disorder |
Alkermes, Inc. |
2015-12 | PHASE1 |
| NCT01567527 | COMPLETED | Bipolar I Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2012-08 | PHASE3 |
| NCT02320032 | COMPLETED | Schizophrenia |
Alkermes, Inc. |
2014-12 | PHASE1 |
| NCT02168920 | TERMINATED | Agitation Associated With Dementia of the Alzheimer's Type |
Otsuka Pharmaceutical Co., Ltd. |
2014-06-11 | PHASE3 |
| NCT02501109 | COMPLETED | Schizophrenia |
CMG Pharmaceutical Co. Ltd |
2015-10 | PHASE1 |
| NCT02069977 | UNKNOWN | Autism |
Yoo-Sook Joung |
2014-02 | PHASE4 |
| NCT02462473 | TERMINATED | Schizophrenia; Schizoaffective Disorder |
Janssen Research & Development, LLC |
2015-05 | PHASE2 |
| NCT01292057 | COMPLETED | Alcohol Dependence |
Medical University of South Carolina |
2011-02 | PHASE3 |
| NCT01942187 | WITHDRAWN | Major Depressive Disorder; Dysthymic Disorder; Depressive Disorder Not Otherwise Specified (NOS) |
New York State Psychiatric Institute |
2013-08 | PHASE4 |
| NCT01942148 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Co., Ltd. |
2010-08 | PHASE3 |
| NCT00884884 | COMPLETED | Alcohol Dependence |
National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
2007-09 | PHASE2; PHASE3 |
| NCT01333072 | COMPLETED | Autistic Disorder |
Medical University of South Carolina |
2011-07 | PHASE4 |
| NCT01421342 | COMPLETED | Major Depressive Disorder |
VA Office of Research and Development |
2012-12 | PHASE3 |
| NCT01119014 | COMPLETED | Psychosis |
Anne Katrine Pagsberg |
2010-05 | PHASE4 |
| NCT02219009 | COMPLETED | Schizophrenia; Mental Disorder; Nervous System Diseases |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2014-08 | PHASE2 |
| NCT01617447 | COMPLETED | Autistic Disorder |
Otsuka Pharmaceutical Co., Ltd. |
2012-07 | PHASE3 |
| NCT00926835 | TERMINATED | Major Depressive Disorder |
Ministry of Health & Welfare, Korea |
2009-05 | PHASE4 |
| NCT02220712 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Co., Ltd. |
2014-07 | PHASE1 |
| NCT01959035 | COMPLETED | Schizophrenia |
H. Lundbeck A/S |
2013-10 | PHASE3 |
| NCT00870727 | COMPLETED | Pervasive Developmental Disorder |
Indiana University |
2009-02 | PHASE3 |
| NCT02137616 | UNKNOWN | Psychotic Disorders |
Central South University |
2012-06 | |
| NCT02040883 | UNKNOWN | Schizophrenia |
Qingyun Yin |
2014-02 | PHASE4 |
| NCT01085383 | COMPLETED | Hyperprolactinemia |
University of Oxford |
2010-04 | PHASE4 |
| NCT00320671 | COMPLETED | Schizophrenia |
Northwell Health |
2005-12 | PHASE4 |
| NCT01942161 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Co., Ltd. |
2010-08 | PHASE2; PHASE3 |
| NCT02087579 | COMPLETED | Psychotic Disorders; Schizophrenia; Bipolar Disorder; Depressive Disorder |
Janssen Research & Development, LLC |
2014-02 | PHASE1 |
| NCT00892047 | COMPLETED | Depression |
University of Pittsburgh |
2009-08 | PHASE4 |
| NCT01795547 | COMPLETED | Schizophrenia |
H. Lundbeck A/S |
2013-02 | PHASE3 |
| NCT01122927 | TERMINATED | Adolescent Schizophrenia; Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2010-07 | PHASE3 |
| NCT01727713 | COMPLETED | Tourette's Disorder; Tic Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2013-01 | PHASE3 |
| NCT02054702 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2014-02 | PHASE3 |
| NCT02192723 | COMPLETED | Schizophrenia |
Beijing HuiLongGuan Hospital |
2012-06 | |
| NCT01981811 | WITHDRAWN | Bipolar 1 Disorder; Schizophrenia; Mental Disorder; Nervous System Diseases |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2014-03 | PHASE2 |
| NCT01154829 | COMPLETED | Schizophrenia |
University of Copenhagen |
2008-12 | |
| NCT02091882 | COMPLETED | Device Latency |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2014-03-21 | PHASE4 |
| NCT01844700 | TERMINATED | High Risk MC4R Genotype; Low Risk MC4R Genotype; One Week or Less Antipsychotic Lifetime Exposure |
Northwell Health |
2013-07 | PHASE4 |
| NCT01416441 | COMPLETED | Tourette's Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2011-10-19 | PHASE3 |
| NCT01418352 | COMPLETED | Tourette's Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2011-08-02 | PHASE3 |
| NCT01909466 | COMPLETED | Schizophrenia; Mental Disorder; Nervous System Diseases |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2013-07 | PHASE1 |
| NCT00806234 | COMPLETED | Psychotic Disorders |
Johns Hopkins University |
2009-01 | PHASE4 |
| NCT02526030 | COMPLETED | Schizophrenia; Psychotic Disorders |
Fundación Marques de Valdecilla |
2008-10 | PHASE4 |
| NCT01683058 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2013-01 | PHASE3 |
| NCT02088697 | COMPLETED | Healthy Volunteers |
Otsuka Pharmaceutical Co., Ltd. |
2013-12 | PHASE1 |
| NCT02013232 | UNKNOWN | Schizophrenia |
Beijing HuiLongGuan Hospital |
2013-02 | |
| NCT01432444 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2011-09 | PHASE3 |
| NCT01813656 | TERMINATED | Methamphetamine Dependence |
Wei Hao |
2012-09 | PHASE4 |
| NCT01742390 | UNKNOWN | Sexual Dysfunction; Hyperprolactinemia |
Si Tianmei |
2013-02 | PHASE4 |
| NCT01813643 | TERMINATED | Methamphetamine Dependence |
Wei Hao |
2012-07 | PHASE4 |
| NCT01157351 | COMPLETED | Schizophrenia |
Janssen Scientific Affairs, LLC |
2010-05 | PHASE4 |
| NCT01418339 | COMPLETED | Tourette's Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2011-07-27 | PHASE3 |
| NCT01149655 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2011-07 | PHASE3 |
| NCT01386086 | COMPLETED | Postpartum Depression |
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |
2011-06 | PHASE3 |
| NCT00731549 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2008-12 | PHASE3 |
| NCT01155544 | WITHDRAWN | Substance Abuse; Substance Dependence |
Northwell Health |
2011-06 | PHASE4 |
| NCT01663532 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2012-10 | PHASE3 |
| NCT01727700 | COMPLETED | Tourette's Disorder; Tic Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2012-11 | PHASE3 |
| NCT01164059 | COMPLETED | Schizophrenia |
University of Bremen |
2010-02 | PHASE4 |
| NCT01520350 | TERMINATED | Bipolar Disorder; Depressive Episode |
Serge Beaulieu |
2012-02 | PHASE3 |
| NCT01710163 | UNKNOWN | Bipolar I Disorder |
University of Sao Paulo |
2012-06 | PHASE4 |
| NCT01592201 | TERMINATED | Schizophrenia |
Janssen Korea, Ltd., Korea |
2012-07 | PHASE4 |
| NCT01429831 | COMPLETED | Major Depressive Disorder |
Taiwan Otsuka Pharm. Co., Ltd |
2011-09 | PHASE4 |
| NCT00737256 | UNKNOWN | Schizophrenia; Cocaine Dependence |
Paul Saenger |
2008-08 | PHASE2 |
| NCT00531518 | COMPLETED | Schizophrenia; Bipolar Disorder; Depression; Psychotic Disorders |
MaineHealth |
2007-10 | |
| NCT00780702 | COMPLETED | Cocaine Dependence; Cocaine-Related Disorders; Opioid-Related Disorders |
National Institute on Drug Abuse (NIDA) |
2008-05-08 | PHASE1 |
| NCT01646827 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2012-05 | PHASE1 |
| NCT01490086 | COMPLETED | Acute Schizophrenia; Schizoaffective Disorder |
Reviva Pharmaceuticals |
2011-12 | PHASE2 |
| NCT01082848 | UNKNOWN | Anorexia Nervosa |
Juan A. Arnaiz |
2010-03 | PHASE3 |
| NCT01109147 | COMPLETED | Schizophrenia, Undifferentiated Type |
Qualissima |
2010-12 | PHASE4 |
| NCT01488266 | UNKNOWN | Major Depressive Disorder |
Korea University |
2011-11 | |
| NCT02435836 | TERMINATED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
1998-04 | PHASE3 |
| NCT01509053 | TERMINATED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2012-01 | PHASE3 |
| NCT00239356 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2003-03 | PHASE3 |
| NCT01129674 | TERMINATED | Schizophrenia |
Eli Lilly and Company |
2010-06 | PHASE2; PHASE3 |
| NCT01328093 | TERMINATED | Schizophrenia |
Denovo Biopharma LLC |
2011-04 | PHASE3 |
| NCT01193166 | WITHDRAWN | Schizophrenia |
Ortho-McNeil Janssen Scientific Affairs, LLC |
2010-08 | PHASE4 |
| NCT00706654 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2008-09-01 | PHASE3 |
| NCT00956189 | COMPLETED | Metabolic Syndrome X |
National Taiwan University Hospital |
2009-11 | |
| NCT00882362 | COMPLETED | Major Depressive Disorder |
Otsuka Pharmaceutical Co., Ltd. |
2009-03 | PHASE3 |
| NCT01001702 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2006-04 | PHASE3 |
| NCT00876343 | COMPLETED | Major Depressive Disorder |
Otsuka Pharmaceutical Co., Ltd. |
2009-03 | PHASE3 |
| NCT00953745 | COMPLETED | Major Depressive Disorder |
Washington University School of Medicine |
2009-05 | |
| NCT00619190 | COMPLETED | Autistic Disorder; Asperger Syndrome; Autism Spectrum Disorder |
University of North Carolina, Chapel Hill |
2006-01 | PHASE2 |
| NCT01009047 | COMPLETED | Schizophrenia |
Janssen Research & Development, LLC |
2009-12 | PHASE3 |
| NCT01227668 | COMPLETED | Irritability Associated With Autistic Disorder |
Bristol-Myers Squibb |
2011-03 | PHASE4 |
| NCT01052389 | COMPLETED | Schizophrenia |
Mario Negri Institute for Pharmacological Research |
2007-07 | PHASE4 |
| NCT00194012 | COMPLETED | Bipolar Disorder |
University Hospitals Cleveland Medical Center |
2004-08 | PHASE3 |
| NCT01607762 | COMPLETED | Healthy |
Janssen Research & Development, LLC |
2012-02 | PHASE1 |
| NCT01552772 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2012-01 | PHASE1 |
| NCT01354353 | COMPLETED | Schizophrenia |
Denovo Biopharma LLC |
2011-05 | PHASE1 |
| NCT00497055 | COMPLETED | Substance Abuse; HIV Infections |
San Francisco Department of Public Health |
2009-03 | PHASE2 |
| NCT00845988 | COMPLETED | Bipolar Disorders; Metabolic Complication |
Seoul National University Hospital |
2008-12 | PHASE4 |
| NCT01026584 | COMPLETED | First Episode Psychosis |
Chonbuk National University Hospital |
2009-10 | PHASE4 |
| NCT01207414 | COMPLETED | Schizophrenia |
Novartis |
2010-08 | PHASE4 |
| NCT00276874 | COMPLETED | Cocaine-Related Disorders |
Craig Rush |
2006-01 | PHASE1 |
| NCT01104766 | COMPLETED | Schizophrenia |
Forest Laboratories |
2010-04-23 | PHASE3 |
| NCT00208533 | COMPLETED | Autism |
Drexel University College of Medicine |
2004-02 | PHASE2 |
| NCT00484471 | COMPLETED | Bipolar Disorder |
Korea Otsuka International Asia Arab |
2007-10 | PHASE4 |
| NCT00665366 | COMPLETED | Bipolar Disorder Mania |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2008-06 | PHASE3 |
| NCT01123707 | TERMINATED | Major Depressive Disorder (MDD) |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2010-11-18 | PHASE3 |
| NCT01111552 | TERMINATED | Major Depressive Disorder (MDD) |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2010-07-29 | PHASE3 |
| NCT01111539 | TERMINATED | Major Depressive Disorder (MDD) |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2010-07-13 | PHASE3 |
| NCT01111565 | TERMINATED | Major Depressive Disorder (MDD) |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2010-10-04 | PHASE3 |
| NCT00198107 | COMPLETED | Autistic Disorder |
Indiana University |
2005-09 | PHASE3 |
| NCT01714011 | COMPLETED | Schizophrenia |
University of Malaya |
2009-05 | PHASE4 |
| NCT01161277 | COMPLETED | Psychosis; Schizophrenia |
Oslo University Hospital |
2010-08 | PHASE4 |
| NCT00667875 | COMPLETED | Alcohol Dependence |
Medical University of South Carolina |
2008-04 | PHASE2 |
| NCT00205699 | COMPLETED | Aggression; Attention Deficit-Hyperactivity; Oppositional Defiant Disorder; Pervasive Development Disorders; Bipolar Disorder |
Washington University School of Medicine |
2006-04 | PHASE4 |
| NCT00509067 | COMPLETED | Schizophrenia |
Georgetown University |
2007-11 | PHASE2 |
| NCT01057849 | UNKNOWN | Schizophrenia |
Peking University |
2008-09 | |
| NCT02305823 | COMPLETED | Schizophrenia; Psychotic Disorders |
Fundación Marques de Valdecilla |
2005-10 | PHASE4 |
| NCT00194077 | COMPLETED | Bipolar Disorder |
University Hospitals Cleveland Medical Center |
2004-08 | PHASE3 |
| NCT00330863 | COMPLETED | Schizophrenia; Schizoaffective Disorder |
Northwell Health |
2006-05 | PHASE4 |
| NCT02534363 | COMPLETED | Schizophrenia; Psychotic Disorders |
Fundación Marques de Valdecilla |
2005-10 | PHASE4 |
| NCT01028820 | COMPLETED | Autism Spectrum Disorder |
University of North Carolina, Chapel Hill |
2009-08 | PHASE4 |
| NCT00352339 | UNKNOWN | Schizophrenia |
Inje University |
2006-08 | PHASE4 |
| NCT00209027 | TERMINATED | Schizophrenia |
Emory University |
2005-04 | |
| NCT00606177 | COMPLETED | Bipolar I Disorder |
Otsuka Pharmaceutical Co., Ltd. |
2008-01 | PHASE3 |
| NCT00606229 | COMPLETED | Bipolar I Disorder |
Otsuka Pharmaceutical Co., Ltd. |
2008-01 | PHASE3 |
| NCT00606320 | COMPLETED | Bipolar I Disorder |
Otsuka Pharmaceutical Co., Ltd. |
2008-01 | PHASE3 |
| NCT00606281 | COMPLETED | Bipolar I Disorder |
Otsuka Pharmaceutical Co., Ltd. |
2008-01 | PHASE3 |
| NCT00746252 | TERMINATED | Bipolar Disorder |
University of Maryland, Baltimore |
2008-06 | |
| NCT00245206 | COMPLETED | Schizophrenia; Alzheimer's Disease; Dementia |
Veterans Medical Research Foundation |
2005-08 | PHASE4 |
| NCT01188668 | COMPLETED | Pharmacokinetics; Cytochrome P-450 CYP2D6; CYP3A4 Protein, Human |
Pfizer |
2010-08 | PHASE4 |
| NCT00905307 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2009-07 | PHASE2 |
| NCT00705783 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2008-07 | PHASE3 |
| NCT01438060 | COMPLETED | Dementia, Alzheimer Type |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2000-08 | PHASE3 |
| NCT01424449 | COMPLETED | Depressive Disorder |
GlaxoSmithKline |
2010-01 | PHASE1 |
| NCT00947154 | COMPLETED | Trichotillomania |
Stanford University |
2009-07 | |
| NCT00545675 | COMPLETED | Bipolar Disorder |
Korea Otsuka Pharmaceutical Co., Ltd. |
2007-12 | PHASE4 |
| NCT00545142 | COMPLETED | Bipolar Disorder |
Korea Otsuka Pharmaceutical Co., Ltd. |
2007-10 | PHASE4 |
| NCT00617058 | TERMINATED | Weight Gain |
University of North Carolina, Chapel Hill |
2007-03 | PHASE2 |
| NCT00845026 | COMPLETED | Schizophrenia |
Denovo Biopharma LLC |
2009-03 | PHASE2 |
| NCT01562808 | COMPLETED | Antipsychotics; Cognition; Brain Metabolism; Dopamine Receptor Occupancy |
Seoul National University Hospital |
2009-01 | |
| NCT00706589 | COMPLETED | Chronic Motor or Vocal Tic Disorder; Tourette's Disorder |
Korea Otsuka Pharmaceutical Co., Ltd. |
2008-10 | PHASE3 |
| NCT00728312 | WITHDRAWN | Methamphetamine Dependence |
US Department of Veterans Affairs |
2009-08 | PHASE4 |
| NCT00592683 | TERMINATED | Pediatric Bipolar Disorder |
Massachusetts General Hospital |
2007-12 | PHASE4 |
| NCT00392197 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Co., Ltd. |
2006-11 | PHASE4 |
| NCT00857818 | TERMINATED | Schizophrenia; Schizoaffective Disorder; Bipolar I Disorder; Metabolic Syndrome |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2009-04 | PHASE3 |
| NCT00420459 | COMPLETED | Fragile X Syndrome |
Indiana University |
2007-04 | PHASE2 |
| NCT01411930 | COMPLETED | Diabetes |
Veterans Medical Research Foundation |
2009-03 | PHASE4 |
| NCT00895921 | COMPLETED | Diabetes |
Veterans Medical Research Foundation |
2008-11 | PHASE4 |
| NCT00910780 | WITHDRAWN | Diabetes |
Washington University School of Medicine |
2009-11 | PHASE2; PHASE3 |
| NCT00276978 | WITHDRAWN | Therapy-resistant Depression |
University Hospital Freiburg |
2005-06 | PHASE3 |
| NCT00468130 | COMPLETED | Autism |
University of Medicine and Dentistry of New Jersey |
2006-05 | |
| NCT00423878 | COMPLETED | Schizophrenia; Schizoaffective Disorder |
National Institute of Mental Health (NIMH) |
2007-01 | PHASE4 |
| NCT00345033 | COMPLETED | Schizophrenia; Insulin Resistance |
Massachusetts General Hospital |
2005-03 | PHASE4 |
| NCT00223496 | COMPLETED | Bipolar Disorder |
The University of Texas Health Science Center at San Antonio |
2004-09 | PHASE4 |
| NCT00439634 | TERMINATED | Schizophrenia |
Sanofi |
2007-02 | PHASE2 |
| NCT00683852 | COMPLETED | Major Depressive Disorder |
Massachusetts General Hospital |
2008-09 | PHASE3 |
| NCT00802100 | COMPLETED | Schizophrenia |
National Institute of Mental Health (NIMH) |
2008-12 | PHASE4 |
| NCT01047215 | UNKNOWN | Schizophrenia; Bipolar |
Taichung Veterans General Hospital |
2009-08 | PHASE4 |
| NCT00205660 | COMPLETED | Schizophrenia; Type 2 Diabetes Mellitus |
Washington University School of Medicine |
2005-02 | PHASE4 |
| NCT00665444 | TERMINATED | Bipolar Disorder; Metabolic Syndrome |
University of Pittsburgh |
2008-04 | |
| NCT00837707 | UNKNOWN | Dyskinesia, Drug-Induced |
Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan |
2008-06 | PHASE4 |
| NCT00277212 | COMPLETED | Bipolar Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2005-12-01 | PHASE4 |
| NCT00365859 | COMPLETED | Autistic Disorder; Behavioral Symptoms |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2006-09-01 | PHASE3 |
| NCT00545467 | COMPLETED | DSM-IV Schizophrenia; Schizoaffective Disorder |
National Taiwan University Hospital |
2007-08 | PHASE4 |
| NCT00261443 | COMPLETED | Bipolar Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2005-09 | PHASE4 |
| NCT00520650 | COMPLETED | Schizophrenia; Schizoaffective Disorder |
Taiwan Otsuka Pharm. Co., Ltd |
2006-08 | PHASE4 |
| NCT00250705 | COMPLETED | Conduct Disorder |
University of Iowa |
2004-11-17 | PHASE4 |
| NCT00044655 | COMPLETED | Schizophrenia |
Icahn School of Medicine at Mount Sinai |
2001-07 | PHASE4 |
| NCT00395915 | UNKNOWN | Schizophrenia |
Universita di Verona |
2006-09 | PHASE4 |
| NCT00508157 | TERMINATED | Metabolic Syndrome; Schizophrenia |
Bristol-Myers Squibb |
2007-11 | PHASE4 |
| NCT00873795 | COMPLETED | Major Depressive Disorder |
Chimei Medical Center |
2007-04 | |
| NCT00363337 | COMPLETED | Bipolar Depression |
Lindner Center of HOPE |
2006-08 | PHASE4 |
| NCT00466310 | COMPLETED | Schizophrenia |
Duke University |
2007-02 | PHASE1 |
| NCT00608543 | COMPLETED | Major Depressive Disorder |
University of Texas Southwestern Medical Center |
2005-10 | PHASE4 |
| NCT00299702 | COMPLETED | Schizophrenia; Psychotic Disorders |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
2006-02 | PHASE4 |
| NCT00288353 | TERMINATED | Schizophrenia; Schizoaffective Disorder; Bipolar Disorder |
Northwestern University |
2006-01 | PHASE3 |
| NCT00308074 | COMPLETED | Autism; Asperger's Disorder; Pervasive Developmental Disorder |
Cambridge Health Alliance |
2006-02 | PHASE2 |
| NCT00288366 | COMPLETED | Schizophrenia; Schizoaffective Disorder; Bipolar Disorder |
Northwestern University |
2006-01 | |
| NCT00712270 | TERMINATED | Schizophrenia |
Kettering Health Network |
2005-04 | PHASE4 |
| NCT00221416 | COMPLETED | Bipolar Disorder |
University of Cincinnati |
2005-06 | PHASE3 |
| NCT01870999 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2007-11 | PHASE1 |
| NCT00580125 | COMPLETED | Schizophrenia |
Pfizer |
2007-11 | PHASE2 |
| NCT00489866 | COMPLETED | PTSD |
Durham VA Medical Center |
2007-03 | PHASE2 |
| NCT00241176 | COMPLETED | Tourette's Syndrome; Tic Disorders |
NYU Langone Health |
2005-09 | PHASE4 |
| NCT00373880 | COMPLETED | Cocaine Abuse |
New York State Psychiatric Institute |
2005-04 | PHASE2 |
| NCT00337571 | COMPLETED | Behavioral Symptoms; Autistic Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2006-06-01 | PHASE3 |
| NCT00374348 | COMPLETED | Schizophrenia OCD; Obsessive Compulsive Disorder |
Jamaica Hospital Medical Center |
2005-03 | |
| NCT00332241 | COMPLETED | Autistic Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2006-06-01 | PHASE3 |
| NCT00105196 | COMPLETED | Major Depressive Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2005-03 | PHASE3 |
| NCT00279409 | TERMINATED | Attention Deficit Hyperactivity Disorder |
New York State Psychiatric Institute |
2006-07 | PHASE2 |
| NCT00347425 | COMPLETED | Schizophrenia and Schizoaffective Disorder |
Solvay Pharmaceuticals |
2006-12 | PHASE3 |
| NCT00556140 | COMPLETED | Psychotic Depression |
Massachusetts General Hospital |
2003-06 | PHASE3 |
| NCT00305370 | COMPLETED | Bipolar Disorder; Attention Deficit Hyperactivity Disorder |
Federal University of Rio Grande do Sul |
2005-08 | PHASE4 |
| NCT00116259 | COMPLETED | Bipolar Disorder; Attention Deficit Hyperactivity Disorder |
Federal University of Rio Grande do Sul |
2005-03 | |
| NCT00226317 | COMPLETED | Bipolar Disorder |
Cambridge Health Alliance |
2004-04 | |
| NCT00257972 | COMPLETED | Bipolar Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2004-10 | PHASE3 |
| NCT00095745 | COMPLETED | Major Depressive Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2004-09 | PHASE3 |
| NCT00216476 | COMPLETED | Schizophrenia; Psychotic Disorders |
Janssen-Cilag International NV |
2004-10 | PHASE3 |
| NCT00338273 | WITHDRAWN | Bipolar Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2006-12 | PHASE3 |
| NCT00292409 | COMPLETED | Schizophrenia and Schizoaffective Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2005-03 | PHASE3 |
| NCT00325689 | COMPLETED | Schizophrenia; Schizoaffective Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2006-07 | PHASE4 |
| NCT00198055 | COMPLETED | Asperger's Disorder; Pervasive Developmental Disorder |
Indiana University |
2005-01 | PHASE2 |
| NCT00300846 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2005-12 | PHASE4 |
| NCT00351936 | COMPLETED | Schizophrenia |
North Suffolk Mental Health Association |
2005-12 | PHASE4 |
| NCT00223418 | COMPLETED | Schizophenia Disorder; Schizoaffective Disorder |
The University of Texas Health Science Center at San Antonio |
2004-01 | |
| NCT00095511 | COMPLETED | Bipolar Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2004-06 | PHASE3 |
| NCT00232687 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2005-06-01 | PHASE4 |
| NCT00221962 | COMPLETED | Attention Deficit Hyperactivity Disorder |
University Hospitals Cleveland Medical Center |
2005-04 | PHASE4 |
| NCT00220636 | COMPLETED | Depressive Disorder, Major |
St. Luke's-Roosevelt Hospital Center |
2005-03 | PHASE4 |
| NCT00102518 | COMPLETED | Schizophrenia; Bipolar Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2004-09 | PHASE3 |
| NCT00237874 | COMPLETED | Schizophrenia; Psychosis |
Yale University |
2004-02 | PHASE2; PHASE3 |
| NCT00110461 | COMPLETED | Bipolar Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2005-03 | PHASE3 |
| NCT00321516 | COMPLETED | Bipolar Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2006-07 | PHASE1 |
| NCT00097266 | COMPLETED | Bipolar Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2004-12 | PHASE3 |
| NCT00095758 | COMPLETED | Major Depressive Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2004-09-01 | PHASE3 |
| NCT00328367 | COMPLETED | Schizophrenia |
Seoul National University Hospital |
2005-12 | PHASE4 |
| NCT00181779 | COMPLETED | Bipolar Disorder; Mania |
Massachusetts General Hospital |
2003-02 | PHASE4 |
| NCT00094432 | COMPLETED | Bipolar I Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2004-06 | PHASE3 |
| NCT00361790 | COMPLETED | Healthy |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2006-08 | PHASE1 |
| NCT00237939 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2002-09 | PHASE3 |
| NCT00080314 | COMPLETED | Bipolar Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2004-01 | PHASE3 |
| NCT00282139 | TERMINATED | Tourette's Syndrome |
University of Florida |
2004-01 | |
| NCT00685334 | COMPLETED | Eating Disorders |
New York State Psychiatric Institute |
2003-11 | PHASE4 |
| NCT00362271 | COMPLETED | Healthy |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2006-08 | PHASE1 |
| NCT00095524 | COMPLETED | Body Weight Change; Schizophrenia; Schizoaffective Disorder; Psychotic Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2004-03 | PHASE3 |
| NCT00095823 | COMPLETED | Major Depressive Disorder |
Bristol-Myers Squibb |
2004-06 | PHASE3 |
| NCT00102063 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2004-07 | PHASE3 |
| NCT00194038 | COMPLETED | Bipolar Disorder |
University Hospitals Cleveland Medical Center |
2004-04 | PHASE4 |
| NCT00304616 | COMPLETED | Schizophrenia |
Korea Otsuka Pharmaceutical Co., Ltd. |
2004-10 | PHASE4 |
| NCT00304655 | COMPLETED | Schizophrenia; Schizoaffective Disorder |
Korea Otsuka Pharmaceutical Co., Ltd. |
2004-07 | PHASE4 |
| NCT00329810 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2005-03 | PHASE4 |
| NCT00211302 | TERMINATED | Schizophrenia; Schizoaffective Disorder |
Louisiana State University Health Sciences Center Shreveport |
2003-08 | |
| NCT00211380 | TERMINATED | Schizophrenia; Schizoaffective Disorder |
Louisiana State University Health Sciences Center Shreveport |
2003-08 | |
| NCT00222833 | COMPLETED | Overweight; Hyperlipidemia; Cardiovascular Diseases |
University of Pittsburgh |
2004-10 | PHASE4 |
| NCT00082199 | COMPLETED | Alcoholism |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2004-04 | PHASE4 |
| NCT00237913 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2004-07 | PHASE3 |
| NCT00102479 | COMPLETED | Schizophrenia; Mania |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2004-07-01 | PHASE1 |
| NCT00095719 | COMPLETED | Dementia; Alzheimer's Disease |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2003-12 | PHASE3 |
| NCT00101569 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2004-03 | PHASE3 |
| NCT00095810 | COMPLETED | Parkinson's Disease; Psychoses |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2003-07 | PHASE4 |
| NCT00080327 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2003-11 | PHASE4 |
| NCT00712686 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2000-06 | PHASE3 |
| NCT00036114 | COMPLETED | Alzheimer Disease |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2000-03 | PHASE3 |
| NCT00036348 | COMPLETED | Bipolar Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2000-03 | PHASE3 |
| NCT00046384 | COMPLETED | Bipolar I Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2002-06 | PHASE3 |
| NCT00041678 | COMPLETED | Alzheimer Disease |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2000-01 | PHASE3 |
| NCT00036101 | COMPLETED | Bipolar Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2002-02 | PHASE3 |
| NCT00036127 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2002-04 | PHASE2; PHASE3 |
| NCT00036361 | COMPLETED | Schizophrenia; Schizoaffective Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2002-07 | PHASE3 |
| NCT00198198 | COMPLETED | Bipolar Depression |
Indiana University |
2005-08 | PHASE4 |
| NCT00689559 | COMPLETED | Alzheimer's Disease |
AstraZeneca |
2008-03 | PHASE1 |
| NCT00468533 | UNKNOWN | Schizophrenia, Tardive Dyskinesia, Metabolic Syndrome |
Yu-Li Hospital |
2006-05 | PHASE4 |
| NCT00177008 | COMPLETED | Schizophrenia; Schizoaffective Disorder; Social Anxiety Disorder |
University of Medicine and Dentistry of New Jersey |
2004-03 | PHASE4 |
| NCT00202007 | COMPLETED | Schizophrenia |
Otsuka Beijing Research Institute |
2005-02 | PHASE2 |
| NCT00169949 | TERMINATED | Prodromal Schizophrenia; Prodromal Psychosis |
Northwell Health |
2004-01 | |
| NCT00634348 | COMPLETED | Schizophrenia |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2004-04 | PHASE4 |
| NCT00174876 | COMPLETED | Depression |
State University of New York - Upstate Medical University |
2004-07 | PHASE2 |
| NCT00103571 | COMPLETED | Schizophrenia |
Eli Lilly and Company |
2004-07 | PHASE4 |
| NCT00438386 | COMPLETED | Generalized Anxiety Disorder; Panic Disorder |
Massachusetts General Hospital |
2005-04 | PHASE4 |
| NCT00089440 | UNKNOWN | Amphetamine-Related Disorders |
National Institute on Drug Abuse (NIDA) |
2004-06 | PHASE1 |
| NCT00183235 | COMPLETED | Alcohol Dependence |
Medical University of South Carolina |
2005-06 | PHASE2 |
| NCT00224822 | COMPLETED | Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Metabolic Syndrome X |
New Mexico VA Healthcare System |
2004-03 | PHASE4 |
| NCT00567099 | UNKNOWN | Schizophrenia; Sensory Gating |
New Mexico VA Healthcare System |
2003-08 | |
| NCT00088049 | COMPLETED | Schizophrenia |
Eli Lilly and Company |
2003-10 | PHASE4 |
| NCT00208169 | COMPLETED | Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Major Depressive Disorder; Anxiety Disorders; Substance Abuse |
Creighton University |
2005-03 | PHASE4 |
| NCT00541554 | UNKNOWN | Hyperprolactinemia; Weight Gain; Dyslipidemia |
Genovate Biotechnology Co., Ltd., |
2007-10 | PHASE4 |
| NCT00167817 | COMPLETED | Schizophrenia |
Veterans Medical Research Foundation |
2003-07 | PHASE4 |
| NCT00283179 | COMPLETED | Schizophrenia; Schizoaffective Disorder |
Taiwan Otsuka Pharm. Co., Ltd |
2004-03 | PHASE3 |
| NCT00440713 | COMPLETED | Posttraumatic Stress Disorder |
Federal University of São Paulo |
2004-01 | PHASE3 |
(data from https://clinicaltrials.gov, updated on 2026-07-31)
Check the
Aripiprazole
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Jump to
Note: Technical data last updated: Sep 1, 2026.